CN1391480A - 治疗过敏性紊乱的组合物及方法 - Google Patents
治疗过敏性紊乱的组合物及方法 Download PDFInfo
- Publication number
- CN1391480A CN1391480A CN00815855A CN00815855A CN1391480A CN 1391480 A CN1391480 A CN 1391480A CN 00815855 A CN00815855 A CN 00815855A CN 00815855 A CN00815855 A CN 00815855A CN 1391480 A CN1391480 A CN 1391480A
- Authority
- CN
- China
- Prior art keywords
- described method
- probiotic bacteria
- compositions
- bacterial species
- level
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 title claims abstract description 60
- 239000000203 mixture Substances 0.000 title claims abstract description 29
- 238000011282 treatment Methods 0.000 title claims description 24
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims description 16
- 208000010668 atopic eczema Diseases 0.000 title claims description 6
- 230000000172 allergic effect Effects 0.000 title description 2
- 239000006041 probiotic Substances 0.000 claims abstract description 67
- 235000018291 probiotics Nutrition 0.000 claims abstract description 67
- 241000894006 Bacteria Species 0.000 claims abstract description 59
- 230000000529 probiotic effect Effects 0.000 claims abstract description 51
- 239000000427 antigen Substances 0.000 claims description 44
- 102000036639 antigens Human genes 0.000 claims description 44
- 108091007433 antigens Proteins 0.000 claims description 44
- 230000001580 bacterial effect Effects 0.000 claims description 35
- 241000894007 species Species 0.000 claims description 31
- 240000001046 Lactobacillus acidophilus Species 0.000 claims description 27
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 claims description 27
- 230000000844 anti-bacterial effect Effects 0.000 claims description 25
- 230000002052 anaphylactic effect Effects 0.000 claims description 23
- 235000013305 food Nutrition 0.000 claims description 18
- 201000010099 disease Diseases 0.000 claims description 14
- 241000186660 Lactobacillus Species 0.000 claims description 12
- 229940039696 lactobacillus Drugs 0.000 claims description 12
- 206010002198 Anaphylactic reaction Diseases 0.000 claims description 11
- 230000036783 anaphylactic response Effects 0.000 claims description 11
- 208000003455 anaphylaxis Diseases 0.000 claims description 11
- 108060003951 Immunoglobulin Proteins 0.000 claims description 10
- 102100037850 Interferon gamma Human genes 0.000 claims description 10
- 108010074328 Interferon-gamma Proteins 0.000 claims description 10
- 108090000978 Interleukin-4 Proteins 0.000 claims description 10
- 102000018358 immunoglobulin Human genes 0.000 claims description 10
- 210000003296 saliva Anatomy 0.000 claims description 9
- 241000124008 Mammalia Species 0.000 claims description 8
- 210000002966 serum Anatomy 0.000 claims description 8
- 244000199866 Lactobacillus casei Species 0.000 claims description 7
- 235000013958 Lactobacillus casei Nutrition 0.000 claims description 7
- 229940017800 lactobacillus casei Drugs 0.000 claims description 7
- 208000006673 asthma Diseases 0.000 claims description 5
- 239000002775 capsule Substances 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 5
- 239000004816 latex Substances 0.000 claims description 5
- 229920000126 latex Polymers 0.000 claims description 5
- 239000000463 material Substances 0.000 claims description 5
- 201000004624 Dermatitis Diseases 0.000 claims description 4
- 238000011284 combination treatment Methods 0.000 claims description 4
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 claims description 3
- 208000004262 Food Hypersensitivity Diseases 0.000 claims description 3
- 206010016946 Food allergy Diseases 0.000 claims description 3
- 206010048908 Seasonal allergy Diseases 0.000 claims description 3
- 239000002671 adjuvant Substances 0.000 claims description 3
- 230000003203 everyday effect Effects 0.000 claims description 3
- 238000002347 injection Methods 0.000 claims description 3
- 239000007924 injection Substances 0.000 claims description 3
- 239000002917 insecticide Substances 0.000 claims description 3
- 238000007912 intraperitoneal administration Methods 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 239000002904 solvent Substances 0.000 claims description 3
- 206010013700 Drug hypersensitivity Diseases 0.000 claims description 2
- 201000005311 drug allergy Diseases 0.000 claims description 2
- 231100000740 envenomation Toxicity 0.000 claims description 2
- 230000002265 prevention Effects 0.000 claims description 2
- 238000002560 therapeutic procedure Methods 0.000 claims description 2
- 238000003018 immunoassay Methods 0.000 claims 1
- 230000001932 seasonal effect Effects 0.000 claims 1
- 239000007909 solid dosage form Substances 0.000 claims 1
- 206010020751 Hypersensitivity Diseases 0.000 abstract 1
- 208000026935 allergic disease Diseases 0.000 abstract 1
- 230000007815 allergy Effects 0.000 abstract 1
- 108010058846 Ovalbumin Proteins 0.000 description 25
- 229940092253 ovalbumin Drugs 0.000 description 25
- 241000699670 Mus sp. Species 0.000 description 22
- 230000005764 inhibitory process Effects 0.000 description 9
- 206010070834 Sensitisation Diseases 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 230000008313 sensitization Effects 0.000 description 6
- 230000005875 antibody response Effects 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 108090000695 Cytokines Proteins 0.000 description 4
- 102000004127 Cytokines Human genes 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 238000010171 animal model Methods 0.000 description 4
- 231100000673 dose–response relationship Toxicity 0.000 description 4
- 235000013618 yogurt Nutrition 0.000 description 4
- 230000000474 nursing effect Effects 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 239000002435 venom Substances 0.000 description 3
- 210000001048 venom Anatomy 0.000 description 3
- 231100000611 venom Toxicity 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 239000013566 allergen Substances 0.000 description 2
- 229910052782 aluminium Inorganic materials 0.000 description 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical group [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 2
- 238000000586 desensitisation Methods 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000008676 import Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 229940039695 lactobacillus acidophilus Drugs 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 210000004303 peritoneum Anatomy 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 1
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 230000005867 T cell response Effects 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 229910021502 aluminium hydroxide Inorganic materials 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 208000035850 clinical syndrome Diseases 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000013213 extrapolation Methods 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000007233 immunological mechanism Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 235000016046 other dairy product Nutrition 0.000 description 1
- 238000002161 passivation Methods 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 206010039083 rhinitis Diseases 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 208000012201 sexual and gender identity disease Diseases 0.000 description 1
- 208000015891 sexual disease Diseases 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 229920002994 synthetic fiber Polymers 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
- G01N33/6869—Interleukin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/07—Bacillus
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/35—Allergens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
- G01N33/6866—Interferon
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/113—Acidophilus
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/125—Casei
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
- G01N2333/335—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Lactobacillus (G)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Cell Biology (AREA)
- Mycology (AREA)
- Food Science & Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Pulmonology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Otolaryngology (AREA)
- Polymers & Plastics (AREA)
- Nutrition Science (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims (51)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AUPQ4158A AUPQ415899A0 (en) | 1999-11-19 | 1999-11-19 | Compositions for and methods of treatment of allergic diseases |
AUPQ4158 | 1999-11-19 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN1391480A true CN1391480A (zh) | 2003-01-15 |
Family
ID=3818302
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN00815855A Pending CN1391480A (zh) | 1999-11-19 | 2000-11-20 | 治疗过敏性紊乱的组合物及方法 |
Country Status (9)
Country | Link |
---|---|
EP (1) | EP1229930A4 (zh) |
JP (1) | JP2003514869A (zh) |
KR (1) | KR20020084066A (zh) |
CN (1) | CN1391480A (zh) |
AU (1) | AUPQ415899A0 (zh) |
BR (1) | BR0015698A (zh) |
CA (1) | CA2391499A1 (zh) |
HK (1) | HK1049115A1 (zh) |
WO (1) | WO2001037865A1 (zh) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111296842A (zh) * | 2020-02-14 | 2020-06-19 | 赵一鸣 | 一种具有抗敏作用的益生菌组合物 |
CN112375722A (zh) * | 2021-01-18 | 2021-02-19 | 山东中科嘉亿生物工程有限公司 | 一种改善过敏的干酪乳杆菌lc-12及其产品、应用 |
CN117085046A (zh) * | 2023-10-20 | 2023-11-21 | 潍坊君薇生物科技有限责任公司 | 嗜酸乳杆菌ls001后生元及其应用 |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ID29150A (id) | 1999-01-15 | 2001-08-02 | Entpr Ireland Cs | Penggunaan lactobacillus salivarius |
FI110668B (fi) * | 2000-06-20 | 2003-03-14 | Aboatech Ab Oy | Probioottien käyttö atooppisten sairauksien primaariseen ehkäisyyn |
PE20030283A1 (es) * | 2001-07-26 | 2003-05-01 | Alimentary Health Ltd | Cepas de lactobacillus casei |
GB0124580D0 (en) | 2001-10-12 | 2001-12-05 | Univ Reading | New composition |
JP4212838B2 (ja) | 2002-06-26 | 2009-01-21 | カルピス株式会社 | 抗アレルギー剤 |
AU2004233658B2 (en) * | 2003-03-13 | 2009-10-29 | Kirin Holdings Kabushiki Kaisha | Antiallergic composition |
JP4712289B2 (ja) * | 2003-08-26 | 2011-06-29 | 株式会社エイ・エル・エイ | 免疫促進用組成物 |
JP4591810B2 (ja) * | 2003-09-19 | 2010-12-01 | 日之出産業株式会社 | 花粉症アレルギー性鼻炎抑制用点鼻組成物 |
AU2004298384A1 (en) * | 2003-12-17 | 2005-06-30 | N.V. Nutricia | Lactic acid producing bacteria and lung function |
US7955834B2 (en) | 2004-06-03 | 2011-06-07 | Biogaia Ab | Method for improved breast milk feeding to reduce the risk of allergy |
TWI356680B (en) * | 2007-01-05 | 2012-01-21 | Promd Biotech Co Ltd | Anti-allergy lactic acid bacteria |
CN102657260B (zh) * | 2007-06-21 | 2013-08-21 | 东宇生物科技股份有限公司 | 抗过敏的乳酸菌 |
CN101328468B (zh) * | 2007-06-21 | 2012-05-23 | 东宇生物科技股份有限公司 | 抗过敏的乳酸菌 |
EP2065048A1 (en) * | 2007-11-30 | 2009-06-03 | Institut Pasteur | Use of a L. casei strain, for the preparation of a composition for inhibiting mast cell activation |
PT2244734T (pt) | 2008-02-01 | 2016-08-05 | Murdoch Childrens Res Inst | Método para induzir tolerância a um alérgeno |
WO2012021432A2 (en) | 2010-08-10 | 2012-02-16 | R.P Scherer Technologies, Llc | Process of manufacturing a stable softgel capsule containing microencapsulated probiotic bacteria |
KR101311989B1 (ko) * | 2010-11-17 | 2013-09-26 | 주식회사한국야쿠르트 | 면역 조절 및 강화 효능을 갖는 락토바실러스 카제이 에이치와이7211를 유효성분으로 함유하는 제품 |
EP3738599B1 (en) * | 2018-01-12 | 2023-12-27 | GI Innovation, Inc. | Composition comprising probiotics and polypeptide having binding affinity for ige and use thereof |
WO2024081219A1 (en) | 2022-10-14 | 2024-04-18 | Csp Technologies, Inc. | Container and method for storing and stabilizing moisture sensitive products |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5946488B2 (ja) | 1978-08-07 | 1984-11-13 | 極東脂肪酸株式会社 | アレルギ−反応抑制剤 |
JPS5946491B2 (ja) | 1979-03-14 | 1984-11-13 | 極東脂肪酸株式会社 | 喘息治療剤 |
JPH07265064A (ja) | 1993-11-23 | 1995-10-17 | Taketoshi Yamada | 腸内細菌叢改善組成物 |
JPH092959A (ja) | 1995-06-16 | 1997-01-07 | Yakult Honsha Co Ltd | IgE抗体産生抑制剤および抗アレルギー剤 |
EP0904784A1 (en) * | 1997-09-22 | 1999-03-31 | N.V. Nutricia | Probiotic nutritional preparation |
JPH11199495A (ja) * | 1998-01-10 | 1999-07-27 | Nichinichi Seiyaku Kk | 腸溶性カプセルを用いた抗アレルギー剤 |
IT1298918B1 (it) * | 1998-02-20 | 2000-02-07 | Mendes Srl | Uso di batteri dotati di arginina deiminasi per indurre apoptosi e/o ridurre una reazione infiammatoria e composizioni farmaceutiche |
JP4074006B2 (ja) * | 1998-06-24 | 2008-04-09 | アサマ化成株式会社 | IgE抗体産生抑制物質の製造方法並びにそれを用いた食品 |
-
1999
- 1999-11-19 AU AUPQ4158A patent/AUPQ415899A0/en not_active Abandoned
-
2000
- 2000-11-20 WO PCT/AU2000/001414 patent/WO2001037865A1/en active Search and Examination
- 2000-11-20 JP JP2001539479A patent/JP2003514869A/ja not_active Withdrawn
- 2000-11-20 BR BR0015698-1A patent/BR0015698A/pt not_active IP Right Cessation
- 2000-11-20 EP EP00975685A patent/EP1229930A4/en not_active Withdrawn
- 2000-11-20 CN CN00815855A patent/CN1391480A/zh active Pending
- 2000-11-20 KR KR1020027006409A patent/KR20020084066A/ko not_active Application Discontinuation
- 2000-11-20 CA CA002391499A patent/CA2391499A1/en not_active Abandoned
-
2003
- 2003-02-11 HK HK03100999.8A patent/HK1049115A1/zh unknown
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111296842A (zh) * | 2020-02-14 | 2020-06-19 | 赵一鸣 | 一种具有抗敏作用的益生菌组合物 |
CN111296842B (zh) * | 2020-02-14 | 2021-01-05 | 赵一鸣 | 一种具有抗敏作用的益生菌组合物 |
CN112375722A (zh) * | 2021-01-18 | 2021-02-19 | 山东中科嘉亿生物工程有限公司 | 一种改善过敏的干酪乳杆菌lc-12及其产品、应用 |
CN117085046A (zh) * | 2023-10-20 | 2023-11-21 | 潍坊君薇生物科技有限责任公司 | 嗜酸乳杆菌ls001后生元及其应用 |
Also Published As
Publication number | Publication date |
---|---|
HK1049115A1 (zh) | 2003-05-02 |
KR20020084066A (ko) | 2002-11-04 |
CA2391499A1 (en) | 2001-05-31 |
BR0015698A (pt) | 2002-07-23 |
WO2001037865A1 (en) | 2001-05-31 |
EP1229930A1 (en) | 2002-08-14 |
EP1229930A4 (en) | 2004-09-22 |
JP2003514869A (ja) | 2003-04-22 |
AUPQ415899A0 (en) | 1999-12-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1391480A (zh) | 治疗过敏性紊乱的组合物及方法 | |
Hedblom et al. | Segmented filamentous bacteria–metabolism meets immunity | |
US20170189455A1 (en) | Prevotella histicola preparations and the treatment of autoimmune conditions | |
Borycka-Kiciak et al. | Butyric acid–a well-known molecule revisited | |
CN1226829A (zh) | 治疗胃肠道损伤的方法 | |
CN1942197A (zh) | 用于改进母乳哺育以减少过敏反应危险性的方法 | |
CN1444484A (zh) | 用益生菌对粘膜表面的细菌或病毒感染进行治疗或免疫治疗及用于此的组合物 | |
Karaffová et al. | Interaction of TGF-β4 and IL-17 with IgA secretion in the intestine of chickens fed with E. faecium AL41 and challenged with S. Enteritidis | |
Sereme et al. | Methanogenic Archaea: emerging partners in the field of allergic diseases | |
Pan et al. | Effect of high dietary manganese on the immune responses of broilers following oral Salmonella typhimurium inoculation | |
Lyu et al. | Modulation of bone remodeling by the gut microbiota: a new therapy for osteoporosis | |
Mortada et al. | Characterizing the immune response of chickens to Campylobacter jejuni (Strain A74C) | |
Zhao et al. | High-throughput sequencing of 16S rRNA amplicons characterizes gut microbiota shift of juvenile sea cucumber Apostichopus japonicus feeding with three antibiotics | |
Foligné et al. | Contribution of the gut microbiota in P28GST-mediated anti-inflammatory effects: experimental and clinical insights | |
Zhang et al. | Lactiplantibacillus plantarum ST-III-fermented milk improves autistic-like behaviors in valproic acid-induced autism spectrum disorder mice by altering gut microbiota | |
Karaffová et al. | Local intestinal immune response including NLRP3 inflammasome in broiler chicken infected with Campylobacter jejuni after administration of Lactobacillus reuteri B1/1 | |
Yun et al. | Regulation of wheat germ polysaccharides in the immune response of mice from newborn to adulthood associated with intestinal microbiota | |
US20210069260A1 (en) | Use of Bacteroides fragilis in preparing drugs for inducing at least one of proliferation and accumulation of &#947;&#948; T cells | |
CN105744844A (zh) | 预防鸡雁小纲动物中坏死性肠炎的制剂 | |
CN109939138A (zh) | 一种抗鸡球虫的中草药微生态制剂及其应用 | |
CN1443075A (zh) | 用于治疗念珠菌病的组合物和方法 | |
CN104161776A (zh) | 来自丁酸梭菌的脂磷壁酸及其调节畜禽免疫应答的用途 | |
DE102011006781A1 (de) | Antikörperprodukt, umfassend n spezifische Antikörper | |
CN106038610B (zh) | 凝结芽孢杆菌在制备用于预防和/或治疗过敏反应的药物中的应用 | |
CN1246056A (zh) | 用于下调免疫系统th2活性的母牛分枝杆菌 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
ASS | Succession or assignment of patent right |
Owner name: ROBERT KRANJ Free format text: FORMER OWNER: PROBIALL PTY LTD. Effective date: 20050701 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20050701 Address after: Sydney, Australia Applicant after: Robert Clanchy Address before: Perth Australia Applicant before: Probiall Pty Ltd. |
|
ASS | Succession or assignment of patent right |
Owner name: DSMIP ASSET CO., LTD. Free format text: FORMER OWNER: ROBERT KRANJ Effective date: 20050819 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20050819 Address after: Holland Heerlen Applicant after: DSMIP N. V. Address before: Sydney, Australia Applicant before: Robert Clanchy |
|
C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
WD01 | Invention patent application deemed withdrawn after publication |